AstraZeneca and SK-Pharmacy: Long-term contract to supply original patented drug at the base of domestic commodity producer
The pharmaceutical giant AstraZeneca signed a long-term contract to supply an original patented drug at the site of JSC NC KAZAKH INVEST.
The signing ceremony was held in the presence of the Chairman of the Board of JSC "NC "KAZAKH INVEST" Yerzhan Yelekeyev, Manager of Government Relations and Public Relations of AstraZeneca Zhalgas Daniyarov, and Acting Chairman of the Management Board of LLP SK-Pharmacy Ruslan Nurmukhanov.
Within the framework of the concluded long-term agreement, AstraZeneca intends to establish contract production and technology transfer in the territory of the Republic of Kazakhstan to ensure full compliance with the requirements of good manufacturing practice (GMP) and organize direct supply of original patented medicines manufactured in Kazakhstan by SK Pharmacy. This critical step will help to increase the availability of high-quality treatments for patients in Kazakhstan. The single distributor takes an active position in the development of cooperation in the field of pharmaceuticals between Kazakhstan, the United Kingdom, and Sweden, initiating several bilateral meetings to consider ways of forming partnerships. Today's conclusion of a long-term contract resulted from all previous agreements and close cooperation with one of the leading pharmaceutical companies.
"Today, we are witnessing the signing of a long-term agreement between AstraZeneca and SK-Pharmacy LLP. It will give a positive impetus to implementing an investment project for the contract production of biotechnological drugs. I want to note the active involvement of the Investment Headquarters under the Government of the Republic of Kazakhstan in this process, at whose meetings issues related to pharmaceutical companies and several BigPharma projects of companies were repeatedly discussed, which in turn developed into separate cases like AstraZeneca," said Yerzhan Yelekeyev, Chairman of the Management Board of KAZAKH INVEST.
"Today, SK-Pharmacy and I signed an important agreement that reflects our company's plans to produce medicines in Kazakhstan. AstraZeneca's innovative drugs will be produced at the site of a domestic manufacturer, Nobel Almaty Pharmaceutical Factory JSC. In particular, it is planned to contract the production of drugs for the treatment of diabetes mellitus, chronic heart failure, chronic kidney disease, for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma, for the treatment of ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, as well as for the treatment of non-small cell lung cancer. We hope that our activities within the framework of a long-term agreement with SK–Pharmacy will help further develop the country's healthcare system and, most importantly, improve the quality of life of our Kazakhstani patients," said Maria Shipuleva, CEO of AstraZeneca in Kazakhstan.
"As a Single Distributor, we express our full readiness to perform our functions within the framework of a Long–term agreement and continue comprehensive work on the dynamic development of the industry, including attracting BigPharma to the domestic pharmaceutical market," said Ruslan Nurmukhanov, Acting Chairman of the Board of SK-Pharmacy.
Cooperation with AstraZeneca will stimulate innovations and the latest scientific developments in Kazakhstan's pharmaceutical industry and improve the skills of Kazakhstani specialists through the exchange of experience. It is worth noting that long-term contracts were previously signed with global industry players such as Pfizer and Roche.
The British-Swedish company AstraZeneca is one of the largest pharmaceutical companies in the world. Its product portfolio includes drugs for therapeutic areas such as cardiology, pulmonology, nephrology, metabolism, respiratory and autoimmune diseases, oncology, and rare diseases.
The pharmaceutical industry is one of the priority areas for the development of the Kazakh economy. The modern pharmaceutical industry, being at the junction of the economic, social, and scientific spheres, demonstrates the social innovation of the state in terms of novelty and accessibility of medicines.
